Evidence map›Paper›PMID 41167683›Full record

ArticleIn vivo (Athens, Greece)

A Case of Combined Small-cell Carcinoma and Adenocarcinoma of the Lung With

Yohei Fukuda, Kosuke Hashimoto, Kyoichi Kaira, Atsuto Mouri, Reina Ishii, Naohito Hashimoto, Y U Miura, Ayako Shiono, O U Yamaguchi, Hisao Imai and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yohei FukudaDepartment of Clinical Training Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Kosuke HashimotoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan hkosuke@saitama-med.ac.jp.
Kyoichi KairaDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Atsuto MouriDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Reina IshiiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Naohito HashimotoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Y U MiuraDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Ayako ShionoDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
O U YamaguchiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Hisao ImaiDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.
Hiroshi KagamuDepartment of Respiratory Medicine, International Medical Center, Saitama Medical University, Saitama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMixed histological lung cancers, such as combined small-cell carcinoma (SCLC) and adenocarcinoma, are rare and often present diagnostic and therapeutic challenges due to intratumoral heterogeneity. In such cases, conventional tissue biopsies may fail to detect key genetic alterations, especially when sampling is limited or affected by tumor evolution. Liquid biopsy has emerged as a complementary approach capable of capturing broader genomic information in a non-invasive manner. CASE REPORT: We describe a 73-year-old woman with metastatic lung cancer initially diagnosed as

conclusionThis case illustrates the clinical value of liquid biopsy in detecting actionable mutations in patients with mixed histological lung cancers where tissue-based testing is inconclusive. Liquid biopsy enabled a personalized therapeutic approach without the need for further invasive procedures. Such strategies may be essential in managing histologically and genomically heterogeneous tumors.

Indexed as

Adenocarcinoma of LungExonsLung NeoplasmsSequence DeletionSmall Cell Lung CarcinomaAcrylamidesAgedAniline CompoundsBiomarkers, TumorErbB ReceptorsFemaleGenomicsHumansIndolesLiquid BiopsyPyrimidinesAcrylamidesAniline CompoundsBiomarkers, TumorEGFR protein, humanErbB ReceptorsIndolesosimertinibPyrimidinesCombined small-cell carcinoma and adenocarcinomaEGFRFoundationOne Liquid CDxliquid biopsy

Identifiers

PMID41167683
PMCPMC12588217

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.